Celldex Therapeutics Stock Market Value
| CLDX Stock | USD 25.39 0.26 1.01% |
| Symbol | Celldex |
Celldex Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.58) | Revenue Per Share 0.164 | Quarterly Revenue Growth 1.103 | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Celldex Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Celldex Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Celldex Therapeutics.
| 11/27/2024 |
| 12/27/2024 |
If you would invest 0.00 in Celldex Therapeutics on November 27, 2024 and sell it all today you would earn a total of 0.00 from holding Celldex Therapeutics or generate 0.0% return on investment in Celldex Therapeutics over 30 days. Celldex Therapeutics is related to or competes with Fate Therapeutics, Caribou Biosciences, and Karyopharm Therapeutics. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific ant... More
Celldex Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Celldex Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Celldex Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 17.16 | |||
| Value At Risk | (6.76) | |||
| Potential Upside | 5.53 |
Celldex Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celldex Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Celldex Therapeutics' standard deviation. In reality, there are many statistical measures that can use Celldex Therapeutics historical prices to predict the future Celldex Therapeutics' volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (0.85) | |||
| Treynor Ratio | (2.03) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celldex Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Celldex Therapeutics Backtested Returns
Celldex Therapeutics secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13% return per unit of risk over the last 3 months. Celldex Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Celldex Therapeutics' Risk Adjusted Performance of (0.13), standard deviation of 3.63, and Mean Deviation of 2.64 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.32, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Celldex Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Celldex Therapeutics is expected to be smaller as well. At this point, Celldex Therapeutics has a negative expected return of -0.43%. Please make sure to confirm Celldex Therapeutics' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Celldex Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.55 |
Modest predictability
Celldex Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Celldex Therapeutics time series from 27th of November 2024 to 12th of December 2024 and 12th of December 2024 to 27th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Celldex Therapeutics price movement. The serial correlation of 0.55 indicates that about 55.0% of current Celldex Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.55 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Celldex Therapeutics lagged returns against current returns
Autocorrelation, which is Celldex Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Celldex Therapeutics' stock expected returns. We can calculate the autocorrelation of Celldex Therapeutics returns to help us make a trade decision. For example, suppose you find that Celldex Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Celldex Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Celldex Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Celldex Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Celldex Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Celldex Therapeutics Lagged Returns
When evaluating Celldex Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Celldex Therapeutics stock have on its future price. Celldex Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Celldex Therapeutics autocorrelation shows the relationship between Celldex Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Celldex Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.